Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

被引：3
|
作者：
Ilyas, Rimal [1 ]
Johnson, Isla McKerrow [1 ]
McCullough, Kristen [2 ]
Al-Kali, Aref [3 ]
Alkhateeb, Hassan B. [3 ]
Begna, Kebede [3 ]
Mangaonkar, Abhishek A. [3 ]
Litzow, Mark R. [3 ]
Hogan, William J. [3 ]
Shah, Mithun, V [3 ]
Patnaik, Mrinal M. M. [3 ]
Pardanani, Animesh [3 ]
Tefferi, Ayalew [3 ]
Gangat, Naseema [3 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Pharmacol, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165491
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1286 / 1287
页数：2
相关论文
共 50 条
  • [21] Body mass index and venetoclax-hypomethylating agent induction therapy for acute myeloid leukemia.
    Weiss, Julian J.
    Le, Henry
    Agarwal, Sonal
    Podoltsev, Nikolai Alexandrovich
    Zeidan, Amer Methqal
    Shallis, Rory
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Srilakshmi
    Gupta, Udita
    Pandya, Vishruti
    Bae, Sejong
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna
    Di Stasi, Antonio
    Vachhani, Pankit
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3245 - 3248
  • [23] Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax plus Hypomethylating Agent
    Gangat, Naseema
    Elbeih, Azeem
    Ghosoun, Nour
    Mccullough, Kristen
    Aperna, Fnu
    Johnson, Isla M.
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Elliott, Michelle
    Mangaonkar, Abhishek
    Matin, Aasiya
    Saliba, Antoine N.
    Torghabeh, Mehrdad Hefazi
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Arana
    Yates, Samuel
    Sneider, Abigail
    Dworkin, Emily
    Patel, Anand A.
    Bazinet, Alexandre
    Senapati, Jayastu
    Bataller, Alex
    Dinardo, Courtney
    Kadia, Tapan
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (02) : 260 - 271
  • [24] Salvage therapy with standard dose cytarabine is appropriate for patients with acute myelogenous leukemia refractory to front-line therapy with hypomethylating agents
    Borthakur, Gautann
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Pierce, Sherry
    Estey, Elihu
    BLOOD, 2007, 110 (11) : 164B - 164B
  • [25] Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia
    Ball, Somedeb
    Jain, Akriti G.
    Aguirre, Luis E. E.
    Al Ali, Najla
    Zhang, Yumeng
    Chan, Onyee
    Kuykendall, Andrew T.
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Swoboda, David
    Komrokji, Rami S.
    Sallman, David A.
    BLOOD, 2021, 138
  • [26] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [27] Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia
    Yu, Guopan
    Yin, Zhao
    Jin, Hua
    Yu, Sijian
    Li, Yuhua
    Nie, Danian
    Guo, Ziwen
    Sun, Zhiqiang
    Meng, Qingxiang
    Zhao, Weihua
    Lin, Dongjun
    Xu, Na
    Zhang, Yu
    BLOOD, 2022, 140 : 11796 - 11796
  • [28] Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia
    Sandhu, Karamjeet S.
    Dadwal, Sanjeet
    Yang, Dongyun
    Mei, Matthew
    Palmer, Joycelynne
    Salhotra, Amandeep
    Al Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Khaled, Samer
    Forman, Stephen J.
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Marcucci, Guido
    Aldoss, Ibrahim
    Pullarkat, Vinod
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) : E322 - E327
  • [29] Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis
    Zimmer, Markie
    Jacob, Brigid
    Spica, Mikayla
    Ghosh, Sunita
    Dabak, Vrushali S.
    BLOOD, 2024, 144 : 6040 - 6041
  • [30] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    BLOOD, 2021, 138
12345